PlumX Metrics
Embed PlumX Metrics

Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial

Antioxidants, ISSN: 2076-3921, Vol: 13, Issue: 8
2024
  • 0
    Citations
  • 0
    Usage
  • 6
    Captures
  • 2
    Mentions
  • 8
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Captures
    6
  • Mentions
    2
    • Blog Mentions
      1
      • Blog
        1
    • News Mentions
      1
      • News
        1
  • Social Media
    8
    • Shares, Likes & Comments
      8
      • Facebook
        8

Most Recent News

Researcher at University of Iowa Describes Research in Cardiovascular Diseases and Conditions (Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial)

2024 SEP 02 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Fresh data on cardiovascular diseases and conditions are presented

Article Description

Chronic kidney disease (CKD) increases the risk of cardiovascular disease and cognitive impairment. Curcumin is a polyphenol that improves vascular and cognitive function in older adults; however, its effects on vascular and cognitive function in patients with CKD are unknown. We hypothesized that curcumin supplementation would improve vascular and cognitive function in patients with CKD. Eighty-eight adults diagnosed with stage 3b or 4 CKD (aged 66 ± 8 years, 75% male) participated in a 12-month, randomized, double-blind, placebo-controlled study to test the effects of curcumin (Longvida, 2000 mg/day) on vascular and cognitive function. Our primary outcome was brachial artery flow-mediated dilation (FMD). Our secondary outcomes were nitroglycerin-mediated dilation, carotid–femoral pulse wave velocity (cfPWV), and cognitive function assessed via the NIH Toolbox Cognition Battery. At baseline, the mean estimated glomerular filtration rate was 34.7 ± 10.8, and the median albumin/creatinine ratio was 81.9 (9.7, 417.3). A total of 44% of participants had diabetes. Compared with placebo, 12 months of curcumin did not improve FMD (median change from baseline was −0.7 (−2.1, 1.1) and −0.1 (−1.5, 1.5) for curcumin and placebo, respectively, with p = 0.69). Similarly, there were no changes in nitroglycerin-mediated dilation, cfPWV, or cognitive outcomes. These results do not support chronic curcumin supplementation to improve vascular and cognitive function in patients with CKD.

Bibliographic Details

Gimblet, Colin J; Kruse, Nicholas T; Geasland, Katharine; Michelson, Jeni; Sun, Mingyao; Ten Eyck, Patrick; Linkenmeyer, Cari; Mandukhail, Safur Rehman; Rossman, Matthew J; Sambharia, Meenakshi; Chonchol, Michel; Kurella Tamura, Manjula; Seals, Douglas; Hoth, Karin F; Jalal, Diana

MDPI AG

Agricultural and Biological Sciences; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know